Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis

The combined use of serum and CSF biomarkers for prognostic stratification in multiple sclerosis (MS) remains underexplored. This multicenter observational study investigated associations between serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), and CSF lipid-specific...

Full description

Bibliographic Details
Authors: Monreal, Enric|||0000-0003-3293-0125; Fernández Velasco, José Ignacio|||0000-0001-9148-671X; Sainz De La Maza, Susana; Espiño, Mercedes; Villarrubia, Noelia; Roldán, Ernesto; Aladro, Yolanda|||0000-0001-9459-5452; Cuello, Juan Pablo; Ayuso-Peralta, Lucía; Rodero-Romero, Alexander; Chico-García, Juan Luís; Rodríguez-Jorge, Fernando; Quiroga-Varela, Ana; Rodríguez-Martín, Eulalia; Pilo, Belén; Martín Ávila, Guillermo; Martínez-Ginés, María Luisa; García Domínguez, José Manuel; Rubio, Lluïsa; Llufriu, Sara|||0000-0003-4273-9121; Comabella López, Manuel|||0000-0002-2373-6657; Montalban, Xavier|||0000-0002-0098-9918; Álvarez-Bravo, Gary; Veiga-Gonzalez, José Luis; Masjuan, Jaime|||0000-0003-1329-0943; Costa-Frossard, Lucienne|||0000-0002-6512-4413; Villar, Luisa M.|||0000-0002-9067-3668
Format: Article
Publication date:2025
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:dnet:uabarcelona_::1c578ac128f1622bcf3d008e03de1815
Online Access:https://ddd.uab.cat/record/328389
https://dx.doi.org/urn:doi:10.3390/ijms26146898
Access Level:Open access
Keyword:Multiple sclerosis
Neurofilament light chain
Glial fibrillary acidic protein
intrathecal IgM synthesis
Progression
Description
Summary:The combined use of serum and CSF biomarkers for prognostic stratification in multiple sclerosis (MS) remains underexplored. This multicenter observational study investigated associations between serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), and CSF lipid-specific IgM oligoclonal bands (LS-OCMB) with different forms of disability worsening, such as relapse-associated worsening (RAW), active progression independent of relapse activity (aPIRA), and non-active PIRA (naPIRA). A total of 535 patients with MS were included, all sampled within one year of disease onset. Biomarkers were quantified using single-molecule array and immunoblotting techniques, and CSF cell subsets were analyzed by flow cytometry. High sNfL z-scores and LS-OCMB positivity were independently associated with increased risk of RAW and aPIRA, collectively termed inflammatory-associated worsening (IAW), while elevated sGFAP levels predicted naPIRA. Patients with both high sNfL and LS-OCMB positivity had the highest risk of IAW. Among LS-OCMB-positive patients, higher regulatory T cell percentages were associated with lower sNfL levels, suggesting a protective role. Conversely, in LS-OCMB-negative patients, sNfL levels correlated with CSF C3 concentrations. These findings support the complementary role of sNfL, sGFAP, and LS-OCMB in identifying distinct mechanisms of disease worsening and may inform early personalized management strategies in MS.